ライフサイエンスコーパス: immune deficiency

1 enhance T-cell survival (eg, vaccination and immune deficiency).

2 Wnt pathway in normal B cell function and FA immune deficiency.

3 in the different segments of the eye due to immune deficiency.

4 , SCFA or dietary fiber intake restores this immune deficiency.

5 s, but also attack normal B cells leading to immune deficiency.

6 nsplantation, and 10% died mostly because of immune deficiency.

7 erturbed by single-gene mutations in primary immune deficiency.

8 identified in patients with common variable immune deficiency.

9 toimmunity, lymphoproliferation, and humoral immune deficiency.

10 gain-of-function mutations may also promote immune deficiency.

11 2 unrelated families in association with an immune deficiency.

12 catalytic subunit, are capable of promoting immune deficiency.

13 stemic diseases and exhibited no evidence of immune deficiency.

14 have been associated with inherited forms of immune deficiency.

15 lammatory autoimmune disease and diseases of immune deficiency.

16 type, which may contribute to age-associated immune deficiency.

17 preventing and/or correcting post-BMT T cell immune deficiency.

18 ral anti-SIV responses, and show no signs of immune deficiency.

19 identify a novel mechanism of age-associated immune deficiency.

20 re an emerging phenotypic subtype of primary immune deficiency.

21 ights into the pathogenesis of KS-associated immune deficiency.

22 immunity, recurrent infections, and combined immune deficiency.

23 ly resulting in a state of predisposition to immune deficiency.

24 hildren given a diagnosis of severe combined immune deficiency.

25 , neurodegeneration, sterility, and acquired immune deficiency.

26 sidered in Amish individuals presenting with immune deficiency.

27 (ICU) patients, even in those without prior immune deficiency.

28 manifested by both B-cell autoreactivity and immune deficiency.

29 nding of the molecular basis of many primary immune deficiencies.

30 sed to investigate the cell biology of human immune deficiencies.

31 n, a common disturbance of atypical clinical immune deficiencies.

32 the context of AIDS and other CD4(+) T cell immune deficiencies.

33 fic associations of autoimmune diseases with immune deficiencies.

34 results in various lymphoid malignancies and immune deficiencies.

35 s and monitoring of patients with cancer and immune deficiencies.

36 nt of VZV infection in patients with certain immune deficiencies.

37 in young foals and in people with underlying immune deficiencies.

38 s with a variety of debilitating diseases or immune deficiencies.

39 hways leading to autoimmune disorders and/or immune deficiencies.

40 interactor (TACI) result in common variable immune deficiency, a syndrome marked by recurrent infect

41 and senescent T cells, lymphadenopathy, and immune deficiency (activated PI3Kdelta syndrome [APDS]).

42 denosine deaminase-deficient severe combined immune deficiency (ADA-SCID) can provide significant lon

43 opic MLV in B6 mice with a range of distinct immune deficiencies affecting antibody production.

44 peutic target in several genetic diseases of immune deficiency affecting cytokine signaling.

45 r the rapid and durable correction of T-cell immune deficiency after BMT, and the induction of tolera

46 se data implicate AD as a cause of secondary immune deficiency after SCI and reveal novel therapeutic

47 to conceptualize the association of primary immune deficiencies and autoimmunity.

48 the complex relationship between the genetic immune deficiencies and autoimmunity.

49 the genetic defect, including other primary immune deficiencies and inborn errors of metabolism.

50 defects, KS is also characterized by humoral immune deficiency and autoimmune disease, yet no detaile

51 Immune deficiency and autoimmunity have been recognized

52 s, but defective inside-out signaling causes immune deficiency and bleeding problems.

53 muL) in the absence of a causal infection or immune deficiency and can manifest with opportunistic in

54 deaminase-deficient forms of severe combined immune deficiency and chronic granulomatous disease.

55 e, which represent models of severe combined immune deficiency and combined immune deficiency with im

56 mune defence pathways, such as the JAK-STAT, immune deficiency and cross-species interferon-gamma pat

57 eatment responses with a specially developed immune deficiency and dysregulation activity score, refl

58 Immune deficiency and dysregulation activity scores were

59 Pre-ART immune deficiency and early immune recovery may contribu

60 orphic alleles typically cause a syndrome of immune deficiency and ectodermal dysplasia.

61 ineous families with childhood-onset humoral immune deficiency and features of autoimmunity shared ge

62 especially those with delayed-onset combined immune deficiency and granulomatous/autoimmune manifesta

63 tion limit nutrients and are associated with immune deficiency and increased susceptibility to infect

64 A 57-year-old woman with common variable immune deficiency and liver failure of unknown etiology

65 ulation of these proteins is associated with immune deficiency and metastasis [1-4].

66 l B-cell differentiation, leading to humoral immune deficiency and, in some cases, autoimmunity.

67 rated antiviral roles of the Drosophila Imd (immune deficiency) and Jak-STAT innate immunity pathways

68 ell-based therapies for cancer, HIV, primary immune deficiencies, and autoimmune diseases, but geneti

69 ients with acquired aplastic anemia, primary immune deficiencies, and congenital bone marrow failure

70 ated the incidence of autoimmune conditions, immune deficiencies, and infections 1-10 years after can

71 ent, elevated risks for autoimmune diseases, immune deficiencies, and infectious conditions may refle

72 benign overgrowth syndromes, cancer, primary immune deficiency, and metabolic syndrome.

73 ity, hypersensitivity to ionizing radiation, immune deficiency, and sterility [1, 2]-phenotypes that

74 thymic epithelial cell (TEC) injury, T-cell immune deficiency, and susceptibility to opportunistic i

75 that lack of TNFR1 leads to a skin-specific immune deficiency, and that resident skin cells have a c

76 cy of PNP in humans causes a specific T-cell immune deficiency, and transition state analogue inhibit

77 ily affected by early-onset IBD, progressive immune deficiency, and, in some cases, autoimmunity and

78 Thus, the onset of overt immune deficiency appears to be intimately linked with C

79 uch as classically syndromic presentation or immune deficiency are often present, in some cases aller

80 T cell homeostasis and it has been linked to immune deficiencies as well as autoimmune disorders.

81 ion is particularly relevant for people with immune deficiencies, as their health depends on treatmen

82 ality for several of the most severe primary immune deficiencies, as well as other inherited disorder

83 HEJ factor, underlie certain severe combined immune deficiencies associated with defective V(D)J reco

84 on promote pathological conditions including immune deficiency, autoimmunity, and cancer.

85 of severe atopy, increased serum IgE levels, immune deficiency, autoimmunity, and motor and neurocogn

86 tations underlie a disorder of severe atopy, immune deficiency, autoimmunity, intellectual disability

87 IL-1R1(-/-) mice did not reflect a systemic immune deficiency, because immunized IL-1R1(-/-) mice su

88 astatic lung cancer model in Severe Combined Immune Deficiency-beige (SCID-bg) mice, should be attrib

89 in human subjects, including severe combined immune deficiency (biallelic null mutations), B-cell exp

90 for the most common forms of severe combined immune deficiency can lead to immune reconstitution in m

91 Thus, an innate immune deficiency can result in unstable gut microbiota

92 ic disorder causing cerebellar degeneration, immune deficiency, cancer predisposition, chromosomal in

93 weeks) or who had chronic pulmonary disease, immune deficiency, cardiac disease, or previous episodes

94 nodeficiency (SCID) known as severe combined immune deficiency caused by adenosine deaminase defects

95 The immune deficiency caused by the Pdia6 mutation was, with

96 ction with a recent biomarker of more severe immune deficiency (CD4 count <200 cells/mL) had a 44% in

97 efects in vitro, which is consistent with an immune deficiency cellular phenotype.

98 nic granulomatous disease (CGD) is a primary immune deficiency characterized by a defect in reactive

99 We conclude that mutations in LRBA cause an immune deficiency characterized by defects in B cell act

100 Common variable immunodeficiency is a rare immune deficiency, characterized by low levels of serum

101 cially true in patients affected by combined immune deficiency (CID), a group of disorders caused by

102 del were older age, male sex, comorbidities (immune deficiency, cirrhosis), Knaus C/D score, and high

103 and convey to patients with common variable immune deficiency (CVID) an increased risk for autoimmun

104 ated with IgA deficiency and common variable immune deficiency (CVID) in humans.

105 Common variable immune deficiency (CVID) is a primary immunodeficiency d

106 Common variable immune deficiency (CVID) is an assorted group of primary

107 Common variable immune deficiency (CVID) is one of the most common conge

108 ated in 10% of patients with common variable immune deficiency (CVID).

109 hip between the underlying diagnoses, severe immune deficiency, cytoreductive regimen, and graft-vers

110 evels of antibodies to patients with primary immune deficiency diseases (PIDD) and for prophylaxis ag

111 The most severe primary immune deficiency diseases (PIDs) have been successfully

112 an centers studying therapy for rare primary immune deficiency diseases (PIDs), including severe comb

113 Primary immune deficiency diseases arise due to heritable defect

114 For many years, severe combined immune deficiency diseases, which are characterized by v

115 e for cardiovascular, neurodegenerative, and immune deficiency diseases.

116 ates, which may advance our understanding of immune-deficiency diseases.

117 inked hyper IgM syndrome (XHM) is a combined immune deficiency disorder caused by genetic alterations

118 ldrich syndrome (WAS) is an X-linked primary immune deficiency disorder resulting from Wiskott-Aldric

119 Persons with primary immune deficiency disorders (PIDD) who receive oral poli

120 plantation (HSCT) is followed by a period of immune deficiency due to a paucity in T-cell reconstitut

121 Combined immune deficiency due to athymia in patients with comple

122 now report on 5 unrelated cases of combined immune deficiency due to hypomorphic RAG mutations, and

123 An acquired immune deficiency due to interferon gamma (IFN-gamma) au

124 s are discovered that cause various forms of immune deficiency, each with their consequent type of in

125 Ectodermal dysplasia with immune deficiency (EDI) is an immunological and developm

126 ning the primary features of common variable immune deficiency, exquisite vulnerability to infection

127 stics from 473 subjects with common variable immune deficiency followed over 4 decades in New York we

128 Severe immune deficiency follows autologous stem cell transplan

129 e.SIGNIFICANCE STATEMENT Conventionally, the immune deficiencies found in ataxia-telangiectasia (A-T)

130 ompted the Medical Advisory Committee of the Immune Deficiency Foundation to issue recommendations ba

131 itution in nonobese diabetic severe combined immune deficiency gamma-/- mice reconstituted with human

132 d either by a distinct pathway involving the immune deficiency gene (imd) or by combined activation o

133 s formation in patients with severe combined immune deficiency, Glanzmann's thrombasthenia, Hermansky

134 and can be characterized by neuropathology, immune deficiency, growth retardation or predisposition

135 Traditionally, primary immune deficiencies have been defined based on increased

136 including Evans syndrome and common variable immune deficiency, have been found to have ALPS.

137 Immune deficiencies highlight the critical role of IFN i

138 Along with this immune deficiency, HIV-1 has been linked to a number of

139 n of individuals with atopic skin disease or immune deficiency, however, can lead to persistent viral

140 erstand the mechanisms driving KS-associated immune deficiency (hypogammaglobulinemia [low IgA], sple

141 t impact immune cell migration and result in immune deficiency illustrate the importance of cell move

142 identified homologs to all of the Drosophila immune deficiency (IMD) and Toll pathway components, an

143 on the activation of two signaling pathways: immune deficiency (IMD) and Toll.

144 iption factor Relish, a key regulator of the Immune deficiency (Imd) IIR signaling pathway.

145 metabolic homeostasis in flies with modified immune deficiency (IMD) pathway activity.

146 ssociated with deregulated activation of the immune deficiency (IMD) pathway of host defense and can

147 (XIAP) acts as a molecular rheostat for the immune deficiency (IMD) pathway of the tick Ixodes scapu

148 The insect immune deficiency (IMD) pathway resembles the tumour nec

149 These responses depend on the immune deficiency (IMD) pathway via activation of the NF

150 The Drosophila immune deficiency (IMD) pathway, homologous to the mamma

151 t this bacterial strain, which activates the immune deficiency (IMD) pathway, is able to replicate an

152 lutionarily conserved signaling cascade, the immune deficiency (Imd) pathway, which activates NF-kapp

153 cells evade death signals by repressing the immune deficiency (IMD) pathway, which operates in paral

154 factors of the NF-B family, the Toll and the immune deficiency (IMD) pathways.

155 c inflammation that leads to deregulation of immune deficiency (IMD) signaling in the midgut of old a

156 of pgrp-lb results in the activation of the immune deficiency (IMD) signaling pathway and leads to t

157 criptionally regulate component genes of the immune deficiency (IMD) signaling pathway and subsequent

158 In Drosophila, immune deficiency (IMD) signalling (tumour necrosis fact

159 nd that fly mutants for RNA interference and immune deficiency (Imd), but not Toll, pathways are more

160 flora and is inhibited by the activities of immune deficiency (Imd), JAK/STAT, and Leu-rich repeat i

161 on innate immune responses controlled by the immune deficiency (IMD), Toll, and other immune signalin

162 Although immune-deficiency (IMD)-mediated immune responses were o

163 fection is causal or secondary to underlying immune deficiencies in CD patients.

164 a cellular dipeptidase implicated in primary immune deficiencies in humans.

165 nd offers a biochemical explanation for rare immune deficiencies in man.

166 alcohol exposure also results in significant immune deficiencies in naive neonates.

167 Together these results show that immune deficiencies in this congenital neutropenia syndr

168 sequencing to examine the genetic causes of immune deficiency in 235 common variable immunodeficienc

169 nutrition (PEM), a common cause of secondary immune deficiency in children, is associated with an inc

170 The specific mechanisms mediating immune deficiency in CVID remain to be determined.

171 The mechanisms underlying immune deficiency in diabetes are largely unknown.

172 oid cell function shows no evidence of overt immune deficiency in HED mutant mice.

173 CVID), the most frequent symptomatic primary immune deficiency in humans, is a heterogeneous group of

174 onstrated multiple phenotypic expressions of immune deficiency in patients with nearly identical geno

175 meostasis using a zebrafish model of primary immune deficiency induced by the human inhibitory Rac2D5

176 assess whether they might contribute to the immune deficiency induced by their T-cell-tropic parenta

177 trol of CMV infection, and correction of the immune deficiency induced by transplant is now clinicall

178 icin as well as other genes regulated by the immune deficiency innate immunity signaling pathway.

179 pressor 1), a negative regulator of the Imd (immune deficiency) innate immune-response pathway.

180 One-by-one, gene therapy for primary immune deficiencies is being brought to the clinic and h

181 Systemic and local immune deficiency is associated with cancer, and the rol

182 Such severe immune deficiency is caused by multiple and profound B c

183 Because a host afflicted with an immune deficiency is not likely to purge a persistent in

184 3 gene encoding kindlin-3 underlie the human immune deficiency known as leukocyte adhesion deficiency

185 ematopoietic malignancies, including anemia, immune deficiency, leukemia, and lymphoma.

186 ive multicenter cohort: the French Childhood Immune Deficiency Long-term Cohort.

187 ster are self-limited, patients with certain immune deficiencies may develop severe or life-threateni

188 Alternatively, underlying immune deficiencies may emerge.

189 Subjects with common variable immune deficiency may have mutations in transmembrane ac

190 lammation supports the notion that an innate immune deficiency might underlie some instances of infla

191 s in mice homozygous for the severe combined immune deficiency mutation in the protein kinase, DNA-ac

192 iseases (PIDD) enrolled in the United States Immune Deficiency Network (USIDNET) registry compared wi

193 The immune deficiency of human immunodeficiency virus (HIV)

194 For patients with immune deficiency or leukemia WBC should be persistently

195 rticularly in elderly patients or those with immune deficiency or underlying lung impairment.

196 o identifying a model of p22(phox)-dependent immune deficiency, our study indicates that a clinically

197 plex prevents constitutive activation of the immune deficiency pathway in response to commensal micro

198 glycan and prevent the induction of tsetse's Immune Deficiency pathway that otherwise can damage the

199 gh activation of the PGRP-LC receptor of the immune deficiency pathway.

200 l peptides associated with both the Toll and Immune deficiency pathways.

201 oll and peptidoglycan recognition protein LC/immune deficiency (PGRP-LC/IMD) signaling pathways.

202 rize the recent advances in treating primary immune deficiency (PID) disorders by stem cell transplan

203 th the burgeoning field of genetics, primary immune deficiencies (PIDs) can be diagnosed and treated

204 Recent studies in patients with primary immune deficiencies (PIDs) have led to important breakth

205 nse variants in a gene implicated in primary immune deficiency, PLCG2, and a negative regulator of in

206 mphoproliferative disease, but the extent of immune deficiency related to R in patients who received

207 It is the causative agent of most immune deficiency-related lymphoproliferative disorders

208 , possibly explaining, at least in part, the immune deficiency reported in some FA patients.

209 sorders, each individual genetic cause of an immune deficiency requires its own vector or editing too

210 will help understand the relevance of innate immune deficiencies responsible for the higher risk of f

211 Innate immune deficiencies result in a spectrum of severe clini

212 ications for the management of patients with immune deficiencies resulting from malnutrition and irra

213 immune deficiencies such as severe combined immune deficiency (SCID) and X-linked agammaglobulinemia

214 ne deaminase (ADA)-deficient severe combined immune deficiency (SCID) may be treated by allogeneic he

215 34(+) cells in the hearts of severe combined immune deficiency (SCID) mice after experimental MI and

216 positive cells injected into severe combined immune deficiency (SCID) mice can transform into cardiom

217 ed by HIV-1 clades using the severe combined immune deficiency (SCID) mouse HIV encephalitis model, w

218 ting in a form of hereditary severe combined immune deficiency (SCID) syndrome.

219 ns that range from T(-) B(-) severe combined immune deficiency (SCID) to Omenn syndrome.

220 inical phenotypes, including severe combined immune deficiency (SCID), autoimmunity, and inflammation

221 y diseases (PIDs), including severe combined immune deficiency (SCID), Wiskott-Aldrich syndrome (WAS)

222 the clinical presentation of severe combined immune deficiency (SCID).

223 T) for infants with X-linked severe combined immune deficiency (SCID-X1) lacking a matched sibling do

224 In addition to treatment of the immune deficiency seen in patients with ADA-SCID, patien

225 ors that is used to prevent or treat primary immune deficiency, several infectious diseases, and auto

226 Eventually, testing for immune deficiencies should more routinely follow a confi

227 omologue for caspar, a negative regulator of immune deficiency signaling pathway.

228 PQ-induced toxicity is mediated through the immune deficiency signaling pathway.

229 te whether a secondary functional neurogenic immune deficiency (spinal cord injury-induced immune def

230 inks mutated POLR3E and Pol III to an innate immune deficiency state in humans.

231 e diseases, malignant diseases, and acquired immune deficiency states (e.g., after organ transplantat

232 therapeutic strategies for the treatment of immune deficiency states, and modulation of exaggerated

233 a range of new, genetically defined, primary immune deficiency states; and (iii) experimental infecti

234 erative BM depression/failure during complex immune deficiencies such as AIDS.

235 loss of gene function, resulting in primary immune deficiencies such as severe combined immune defic

236 The acquired immune deficiency syndrome (AIDS) epidemic was first rec

237 Diarrhea in patients with acquired immune deficiency syndrome (AIDS) has proven to be both

238 s, which gave rise to HIV-1 and the acquired immune deficiency syndrome (AIDS) pandemic.

239 SCD criteria, 131 (57%) were due to acquired immune deficiency syndrome (AIDS), 25 (11%) were due to

240 ection on mortality from HIV and/or acquired immune deficiency syndrome (AIDS), and hepatitis or live

241 y in immunocompromised persons with Acquired Immune Deficiency Syndrome (AIDS), and to the developmen

242 human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), effectively serving a

243 portions, timing, and predictors of acquired immune deficiency syndrome (AIDS)-related and non-AIDS-r

244 that drives clinical progression to acquired immune deficiency syndrome (AIDS).

245 an Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS).

246 l nervous system (CNS) pathology of acquired immune deficiency syndrome (AIDS).

247 an immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS).

248 gainst human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).

249 lcoholism along with other factors (acquired immune deficiency syndrome [AIDS]-defining events, hepat

250 samples from an infant with severe combined immune deficiency syndrome and persistent RSV infection.

251 human immunodeficiency virus (HIV)/acquired immune deficiency syndrome are complex and not completel

252 itive individual who presented with acquired immune deficiency syndrome despite repeatedly negative H

253 by the human immunodeficiency virus/acquired immune deficiency syndrome epidemic.

254 In a single-center study, all HIV/acquired immune deficiency syndrome patients with complete clinic

255 rus encephalitis causes dementia in acquired immune deficiency syndrome patients.

256 nfection in 25% of immunosuppressed acquired immune deficiency syndrome patients.

257 s, and human immunodeficiency virus/acquired immune deficiency syndrome therapy, mechanical hyperalge

258 deficiency virus (HIV) causes AIDS (acquired immune deficiency syndrome), a disease in which the immu

259 rtality, accelerates progression to acquired immune deficiency syndrome, and exacerbates tuberculosis

260 cacy in the rhesus macaque model of acquired immune deficiency syndrome, enabling 50% of vaccinated m

261 l for investigating Tfh role in HIV/acquired immune deficiency syndrome, given its slow rate of CD4 d

262 1 (HIV-1), the retroviral agent of acquired immune deficiency syndrome, requires several host factor

263 mmune deficiency (spinal cord injury-induced immune deficiency syndrome, SCI-IDS) may account for the

264 en more than 1 comorbidity), and nonacquired immune deficiency syndrome-defining malignancy (HR = 2.0

265 or epidemiologic studies of HIV and acquired immune deficiency syndrome.

266 ion of CD4(+) T cells that leads to acquired immune deficiency syndrome.

267 defined as CD4 of <200 cells/muL or acquired immune deficiency syndrome.

268 ranscriptase inhibitors (NRTIs) for acquired immune deficiency syndrome.

269 human immunodeficiency virus (HIV)/acquired immune deficiency syndrome; however, liver pathology dat

270 It is a unique example of an immune deficiency that is linked to dysfunctional mitoch

271 the ongoing gene therapy trials for primary immune deficiencies, the first reports of new trials and

272 The persistence of immune deficiency throughout life suggests that the cell

273 iency, ranging from T(-)B(-) severe combined immune deficiency to delayed-onset disease with granulom

274 une dysregulation, such as combined variable immune deficiency, transporter associated with antigen p

275 ed in patients with X-linked Severe Combined Immune Deficiency treated with gene therapy because of r

276 The Primary Immune Deficiency Treatment Consortium (PIDTC) is a coll

277 The Primary Immune Deficiency Treatment Consortium (PIDTC) is a netw

278 The Primary Immune Deficiency Treatment Consortium (PIDTC) is enroll

279 The Primary Immune Deficiency Treatment Consortium attempted to deve

280 nts with WAS who underwent HCT at 29 Primary Immune Deficiency Treatment Consortium centers from 2005

281 The Primary Immune Deficiency Treatment Consortium was formed to ana

282 an Society for Immunodeficiency, and Primary Immune Deficiency Treatment Consortium.

283 That an engineered innate immune deficiency ultimately results in spontaneous inte

284 -type plasminogen activator, severe combined immune deficiency (uPA-SCID) mice" (chimeric mice).

285 duals suggesting its potential role in human immune deficiency virus (HIV)-associated neuroinflammati

286 The human immune deficiency virus type 1 (HIV-1) matrix protein p1

287 des, which could detect anti-p17 (HIV, human immune deficiency virus) antibodies (Ab) in phosphate bu

288 Human Immune Deficiency Virus-1 (HIV-1) infection can induce s

289 Immune deficiency viruses such as SIV in macaques or HIV

290 w of the literature regarding PML in primary immune deficiencies we found 26 cases, only 54% of which

291 ious mechanisms of humoral and cell-mediated immune deficiencies, which mainly depend on underlying d

292 ral PIDs, including forms of severe combined immune deficiency, Wiskott-Aldrich syndrome, and chronic

293 rted as a monogenic cause of common variable immune deficiency with features of immune dysregulation.

294 vere combined immune deficiency and combined immune deficiency with immune dysregulation, respectivel

295 ency is a novel autosomal recessive combined immune deficiency with impaired clathrin-mediated endocy

296 E syndrome, Job syndrome, HIES) is a complex immune deficiency with multiorgan clinical manifestation

297 umans, manifesting by a progressive combined immune deficiency with severe autoimmune disease.

298 y EXTL3 mutations as a novel cause of severe immune deficiency with skeletal dysplasia and developmen

299 aretroviral gene therapy for severe combined immune deficiency-X1, adenosine deaminase-deficient form

300 that disrupt TCR signaling can cause severe immune deficiency, yet less disruptive variants are some